<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04399395</url>
  </required_header>
  <id_info>
    <org_study_id>32772</org_study_id>
    <nct_id>NCT04399395</nct_id>
  </id_info>
  <brief_title>Naltrexone/Bupropion (Mysimba) to Optimize Weight Outcomes After Obesity Surgery</brief_title>
  <official_title>Treatment With Naltrexone/Buprpion (Mysimba) to Optimize Weight Outcomes After Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Limited/poor weight loss and weight regain are concerns following bariatric surgery, and&#xD;
      weight regain may increase the risk for relapse of comorbidities related to obesity.&#xD;
      Medications for weight reduction may assist further weight loss, and support weight&#xD;
      maintenance, with positive effects on comorbidities. This pilot study will examine the effect&#xD;
      of naltrexone/bupropion and lifestyle advice versus lifestyle advice alone for 7 months in&#xD;
      patients with a suboptimal weight trajectory (either little weight loss or weight regain) 2&#xD;
      years or later following bariatric surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study aim and endpoints The aim of this pilot study is to evaluate the effect of Mysimba in&#xD;
      patients with suboptimal weight loss or weight regain after bariatric surgery. The primary&#xD;
      endpoint is body weight.&#xD;
&#xD;
      Objective The study objective is to understand whether patients with suboptimal weight loss&#xD;
      or weight regain 2 years or more following bariatric surgery achieve better weight loss with&#xD;
      Mysimba and dietary counselling compared with a control group treated with dietary&#xD;
      counselling alone.&#xD;
&#xD;
      This is a phase IV, open label randomized controlled study conducted over 7 months with a&#xD;
      3-month post-intervention follow-up. The study will be conducted in accordance with good&#xD;
      clinical practice. Patients meeting eligibility criteria will be randomized into one of two&#xD;
      groups: an intervention group treated with Mysimba and lifestyle and a control group treated&#xD;
      with lifestyle. The intervention group will be prescribed Mysimba gradually titrated to the&#xD;
      maximum tolerated dose (maximum dose is 32 mg/360 mg divided in 4 tablets) with 2 week&#xD;
      intervals. Both groups will receive the same follow up including dietary counselling during&#xD;
      the course of the study. Randomization will be done using a standard internet-based program&#xD;
      where group assignment cannot be anticipated. The study is not blinded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Covid-pandemic&#xD;
  </why_stopped>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>7 months</time_frame>
    <description>Body weight</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Lifestyle and naltrexone/bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone/bupropion</intervention_name>
    <description>Approved drug for obesity treatment</description>
    <arm_group_label>Lifestyle and naltrexone/bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle</intervention_name>
    <description>Lifestyle</description>
    <arm_group_label>Lifestyle</arm_group_label>
    <arm_group_label>Lifestyle and naltrexone/bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Men and women aged 18-65 years who have undergone RYGB, mini-RYGB or sleeve gastrectomy 2&#xD;
        or more years previously and either&#xD;
&#xD;
          1. Have a percent total weight loss from time of surgery of &lt;20% OR&#xD;
&#xD;
          2. Have a regain of at least 5% or more of nadir weight (lowest weight at 12-18 months&#xD;
             after surgery) AND&#xD;
&#xD;
          3. Meet current clinical criteria for use of Mysimba (BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with&#xD;
             obesity-related comorbidity (diabetes type 2, controlled hypertension, dyslipidemia)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serious illness or complications due to bariatric surgery according to the judgement&#xD;
             of the investigators and clinical records&#xD;
&#xD;
          -  Use of any weight loss medications following bariatric surgery&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Participation in other weight loss studies&#xD;
&#xD;
          -  Contraindication for use of Mysimba. These include but are not limited to epilepsy or&#xD;
             history of seizure, uncontrolled hypertension (blood pressure ≥150/95 mmHg with or&#xD;
             without medication), previous or current eating disorder, substance abuse, bipolar&#xD;
             depression, serious liver or kidney disease, use of certain medications)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serena Tonstad, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2020</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Serena Tonstad</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

